首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents
【24h】

Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents

机译:N-取代的2-氨基噻唑衍生物作为抗结核药的构效关系的设计,合成与研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Tuberculosis (TB) is one of the deadliest infectious diseases of all times, and its recent resurgence is a supreme matter of concern. Co-infection with HIV and, in particular, the continuous isolation of new resistant strains, makes the discovery of novel anti-TB agents a strategic priority. The research of novel agents should be driven by the accessibility of the synthetic procedure and, in particular, by the lack of cross-resistance with the drugs already marketed. Moreover, in order to shorten the duration of the therapy, and therefore decrease the rate of resistance, these molecules should be active also against the nonreplicating persistent form (NRP-TB) of the infection. The availability of an in-house small library of compounds prompted us to investigate their anti-TB activity. Two compounds, embodying a 2-aminothiazole scaffold, were found to possess a certain inhibitory activity toward Mycobacterium tuberculosis H37Rv, and therefore a medicinal chemistry campaign was initiated in order to increase the activity of the hit compounds and, especially, construct a plausible body of structure-activity relationships. The potency of the hit compound was successfully improved, and, much more importantly, some of the molecules synthesized were found to be active toward the persistent phenotype, and, also, toward a panel of resistant strains. These findings encourage further investigations around this interesting antitubercular chemotype.
机译:结核病(TB)是有史以来最致命的传染病之一,其近期的复苏是一个值得关注的最高问题。与HIV共同感染,尤其是不断分离出新的耐药菌株,使得发现新型抗结核病药物成为战略重点。新型药物的研究应由合成方法的可及性,尤其是与已经上市的药物缺乏交叉耐药性来推动。此外,为了缩短治疗时间并因此降低耐药率,这些分子还应具有抗感染的非复制性持久形式(NRP-TB)的活性。内部小型化合物库的可用性促使我们研究其抗结核活性。发现包含2-氨基噻唑骨架的两种化合物对结核分枝杆菌H37Rv具有一定的抑制活性,因此发起了药物化学运动,以提高命中化合物的活性,特别是构建了可能的化合物。结构-活动关系。成功提高了命中化合物的效价,更重要的是,发现一些合成的分子对持久表型具有活性,并且对一组耐药菌株也具有活性。这些发现鼓励围绕这种有趣的抗结核化学型进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号